Blueprint Medicines Corporation

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:50:49 2024-05-16 pm EDT			5-day change	1st Jan Change
106.3 ^USD	-0.50%		-2.19%	+14.89%

May. 14	Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target	MT
May. 06	Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	MT

Blueprint Medicines Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023

August 02, 2023 at 07:01 am EDT

Blueprint Medicines Corporation reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 57.57 million compared to USD 36.55 million a year ago. Net loss was USD 132.79 million compared to USD 159.71 million a year ago. Basic loss per share from continuing operations was USD 2.19 compared to USD 2.68 a year ago.
For the six months, revenue was USD 120.86 million compared to USD 99.28 million a year ago. Net loss was USD 262.35 million compared to USD 265.71 million a year ago. Basic loss per share from continuing operations was USD 4.35 compared to USD 4.47 a year ago.

Latest news about Blueprint Medicines Corporation

Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target	May. 14	MT
Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing	May. 06	MT
Goldman Sachs Adjusts Price Target on Blueprint Medicines to $168 From $121, Maintains Buy Rating	May. 06	MT
Leerink Upgrades Blueprint Medicines to Market Perform, Price Target at $97	May. 06	MT
Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating	May. 02	MT
Blueprint Medicines Shares Rise After Q1 Swings to Net Income, Revenue Rises	May. 02	MT
Transcript : Blueprint Medicines Corporation, Q1 2024 Earnings Call, May 02, 2024	May. 02
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Posts Q1 Revenue $96.1M, vs. Street Est of $81.4M	May. 02	MT
Blueprint Medicines Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Blueprint Medicines Corporation Revises Revenue Guidance for the Full Year 2024	May. 02	CI
Transcript : Blueprint Medicines Corporation - Special Call	Apr. 25
Blueprint Medicines Insider Sold Shares Worth $2,188,265, According to a Recent SEC Filing	Mar. 22	MT
Blueprint Medicines Insider Sold Shares Worth $500,000, According to a Recent SEC Filing	Mar. 01	MT
Blueprint Medicines Says Ayvakit Data in Indolent Systemic Mastocytosis Show Long-Term Efficacy, Safety	Feb. 23	MT
Blueprint Medicines Highlights AYVAKIT (Avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting	Feb. 23	CI
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO	Feb. 22	CI
Wedbush Adjusts Blueprint Medicines' PT to $110 From $97, Keeps Outperform Rating	Feb. 15	MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises; Shares Up	Feb. 15	MT
Blueprint Medicines Q4 Loss Narrows, Revenue Rises	Feb. 15	MT
Transcript : Blueprint Medicines Corporation, Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15
Earnings Flash (BPMC) BLUEPRINT MEDICINES CORPORATION Reports Q4 Revenue $72M, vs. Street Est of $67.1M	Feb. 15	MT
Blueprint Medicines Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 15	CI
Blueprint Medicines Corporation Provides Revenue Guidance for the Full Year 2024	Feb. 15	CI
Barclays Increases Price Target on Blueprint Medicines to $70 From $58, Maintains Equalweight Rating	Feb. 13	MT
Oppenheimer Raises Blueprint Medicines Price Target to $90 From $85, Maintains Outperform Rating	Jan. 31	MT

Chart Blueprint Medicines Corporation

Duration

Period

More charts

Company Profile

Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-06-10 - Goldman Sachs Global Healthcare Conference

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Blueprint Medicines Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

106.8 USD

Average target price

119.4 USD

Spread / Average Target

+11.82%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BLUEPRINT MEDICINES CORPORATION	+14.89%	6.69B
MODERNA, INC.	+33.13%	49.46B
IQVIA HOLDINGS INC.	+1.73%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.53%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.68%	18.64B
BIO-TECHNE CORPORATION	+8.13%	13.16B
MEDPACE HOLDINGS, INC.	+29.18%	12.55B
UNITED THERAPEUTICS CORPORATION	+24.33%	12.1B

Other Biotechnology & Medical Research